Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drop targets dry eye by gene type

NCT ID NCT07548632

Symptom relief Sponsor: Oculis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 3 times

Summary

This study tests whether licaminlimab eye drops can reduce eye discomfort in people with dry eye disease who have a specific gene variant. About 160 participants will use the drops three times daily for 29 days. The goal is to see if this targeted approach works better than a placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
licaminlimab eye drops
What this could lead to
If it works, this could point toward a new treatment option for dry eye disease in people with a specific genetic profile.
What could go wrong
This is an early-to-mid stage trial with only 160 participants, so results may not apply to everyone. The treatment may not be more effective than placebo eye drops.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Physician diagnosis of Dry Eye Disease in the past 6 months * Use of over-the-counter tears * Must agree to genotype testing Key Exclusion Criteria: \- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye disease (DED) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry eye disease (DED)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    12 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • CORE, Inc

    RECRUITING

    Shelby, North Carolina, 28150, United States

  • East West Eye Institute

    RECRUITING

    Aliso Viejo, California, 92656, United States

  • Erie Retina Research

    RECRUITING

    Erie, Pennsylvania, 16507, United States

  • Eye Research Foundation

    RECRUITING

    Newport Beach, California, 92664, United States

  • Global Research Management

    RECRUITING

    Glendale, California, 91204, United States

  • LoBue Laser and Eye Medical Center

    RECRUITING

    Murrieta, California, 92562, United States

  • North Bay Eye Associates, Inc.

    RECRUITING

    Petaluma, California, 94954, United States

  • Oculus Research, Inc.

    RECRUITING

    Garner, North Carolina, 27529, United States

  • Orange County Ophthalmology

    RECRUITING

    Garden Grove, California, 92843, United States

  • Piedmont Eye Center, Inc.

    RECRUITING

    Lynchburg, Virginia, 24502, United States

  • Scott & Christie and Associates

    ACTIVE_NOT_RECRUITING

    Cranberry Township, Pennsylvania, 16066, United States

  • Segal Drug Trials, Inc.

    ACTIVE_NOT_RECRUITING

    Delray Beach, Florida, 33484, United States

  • Total Eye Care, PA

    RECRUITING

    Memphis, Tennessee, 38119, United States

  • Vision Institute

    RECRUITING

    Colorado Springs, Colorado, 80907, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.